Purpose: To evaluate the safety and efficacy of a five-day regimen of oral 5-fluorouracil (5-FU) plus eniluracil (776C85) in patients with metastatic colorectal cancer (CRC).
Introduction
5-fluorouracil (5-FU) has been in clinical use for more than 40 years and remains one of the most commonly prescribed chemotherapy agents for the treatment of patients with solid tumors. Over the years, attempts have been made to improve the clinical utility of 5-FU through biochemical modulation and manipulation of infusion schedules. Despite these efforts, the antitumor activity of 5-FU remains suboptimal. Strategies for biochemical modulation have focused mainly on 5-FU activation (anabolic) pathways, and, until recently, the inactivation (catabolic) pathways have received relatively little attention.
The biochemical rationale for the enhancement of 5-FU cytotoxicity by LV has been well described [1] . Therapy with 5-FU plus LV administered iv on either a weekly or monthly schedule showed a highly significant benefit over single-agent 5-FU in terms of tumor response rate (23% vs. 11%) in a meta-analysis of nine randomized clinical trials performed by the Advanced Colorectal Cancer Meta-Analysis Project [2] . The increase in response rate did not, however, translate into a survival benefit for patients treated with the combination compared with those receiving 5-FU alone.
The regimen of i.v. 5-FU immediately following i.v. LV given for five consecutive days every four weeks, which was developed by the North Central Cancer Treatment Group and Mayo Clinic, has been reported to produce improved survival versus that of i.v. 5-FU alone in patients with previously untreated metastatic CRC [3] . However, this combination is also associated with increased severe gastrointestinal toxicity. This regimen has since become a standard treatment regimen in the US for the initial treatment of patients with metastatic CRC.
The bioavailability of a 25 mg dose of oral LV is 97% [4] . Following oral administration, LV is rapidly absorbed and enters the general body pool of reduced folates, predominantly as 5-methyltetrahydrofolate [5] . In a randomized prospective trial of i.v. 5-FU versus i.v. 5-FU plus oral LV, the latter combination produced the same efficacy and toxicity pattern as that reported for intravenous 5-FU and LV [6] . Therefore, it appears that oral LV can be substituted for the i.v. LV administered as part of the NCCTG-Mayo Clinic regimen.
Dihydropyrimidine dehydrogenase (DPD) is the first and rate-limiting enzyme in the 5-FU catabolic pathway. Eniluracil inactivates DPD and thereby blocks 5-FU catabolism. Inactivation of DPD by eniluracil increases the oral bioavailability and reduces the pharmacokinetic variability of 5-FU [7] . Eniluracil also eliminates the formation of 5-FU catabolites that appear to cause toxicity and may interfere with 5-FU activity [8] . It has been reported that intratumoral DPD expression correlates inversely with response to 5-FU based therapy in patients with head and neck cancer [9] . Inactivation of DPD in tumors may, therefore, provide a mechanism for overcoming tumor 5-FU resistance.
The purpose of this open-label phase II study (FUMA 2001) was to evaluate the safety and efficacy of an orally administered regimen of eniluracil given together with 5-FU or 5-FU plus LV. The administration schedule selected was based on the NCCTG-Mayo Clinic regimen and on the results of a phase I trial conducted at the University of Chicago and the University of Texas at San Antonio [10] . The efficacy of these two regimens (eniluracil-5-FU alone or with LV) was evaluated in patients with metastatic CRC divided into two strata: those who had not received previous chemotherapy and those who had failed to respond to chemotherapy with i.v. 5-FU plus LV. The information derived from this trial was used to guide the future development of eniluracil-5-FU when given on this schedule.
Patients and methods
Patients with previously untreated metastatic CRC or metastatic CRC refractory to 5-FU plus LV were enrolled at five institutions. Previously untreated patients were defined as those who had received no prior chemotherapy for metastatic disease and no adjuvant chemotherapy within the previous six months. Patients with refractory disease were defined as those who had disease progression during or within two months of their last dose of i.v. 5-FU-LV either as treatment for metastatic disease or as adjuvant therapy.
For the purpose of analysis, patients with refractory disease were then divided into two sub-strata based on their response to previous therapy. These were defined as follows: patients with primary resistance were those who had neither an objective tumor response nor a period of stable disease of at least two months duration during treatment with 5-FU-LV for metastatic disease, or disease progression during or within two months of receiving adjuvant 5-FU-LV; patients with acquired resistance were those who had an objective tumor response or a period of stable disease while still receiving, or within two months of receiving, their final dose of 5-FU-LV for treatment of metastatic disease. Written informed consent was obtained from all patients. The study was approved by the institutional review board of the participating institutions.
weeks and ability to swallow and retain oral medication. Patients were required to have adequate organ function as defined by: hemoglobin of 9 gm/dl or higher, granulocyte count at least 1500/mm 3 , platelet count at least 100,0007mm 3 , estimated creatinine clearance at least 50 ml/min, total bilirubin < 1.5 x the upper limit of normal, and AST or ALT $ 3 x the upper limit of normal. Patients with known central nervous system metastases were excluded, and patients were not allowed to have received previous chemotherapy for metastatic colorectal cancer other than bolus intravenous 5-FU plus LV. Treatment with 5-FU-LV was not permitted in the four weeks preceding enrollment onto the study.
Treatment
A schematic representation of the study design is shown in Figure 1 . The study was designed to enroll an estimated total of 78 patients, 22 with previously untreated metastatic CRC and 56 with metastatic CRC refractory to 5-FU-LV. Enrollment in the two treatment groups proceeded concurrently. The actual numbers of patients in each stratum and treatment group are shown in Figure 1 .
All patients received seven consecutive daily doses of eniluracil at a fixed dose of 20 mg/day, with once daily doses of 5-FU given on days 2-6. Treatment was repeated every four weeks. Half of the patients in each stratum also received 50 mg/day LV on days 2-6. The 5-FU dose was 25 mg/m 2 when administered without LV and 20 mg/m 2 when administered with LV. All drugs were administered orally. Patients continued treatment until progression of disease or unmanageable toxicity warranted their removal from the study. Eniluracil and 5-FU were supplied by Glaxo Wellcome; eniluracil as 5 mg and 10 mg tablets and 5-FU as 5 mg and 25 mg tablets. The LV used in this study was obtained commercially by the study sites as 25 mg tablets. The dose of eniluracil remained constant throughout the study. Patients were instructed that consecutive daily doses of eniluracil should be taken no more than 24 hours apart. For the first 20 patients enrolled on the study, the actual 5-FU dose was rounded up to the nearest 5 mg. Due to an unexpectedly high incidence of grade 4 neutropenia, the method of calculation for the 5-FU dose was changed for the remaining patients, and the actual 5-FU dose was rounded down to the nearest 5mg.
Dose modifications
No modifications were made to the eniluracil and LV doses. Patients were required to meet the following criteria to begin a subsequent course of treatment: platelets at least 75,000/mm 3 , granulocytes at least 1500/mm 3 , and resolution of all clinically significant non-hematologic toxicities to baseline. Treatment of patients who did not meet these criteria was delayed until the requirements were met. Patients requiring a delay of more than three weeks were taken off treatment. For subsequent courses, the dose of 5-FU was modified based upon the maximum intensity of hematologic and non-hematologic drug-related toxicity that occurred in the previous course. Toxicity was evaluated weekly in patients on treatment, and intensity was graded according to modified Southwest Oncology Group (SWOG) toxicity criteria [11] . The modified 5-FU dosage was a percentage of the previous 5-FU dosage calculated according to Table 1 . Once a dose of 5-FU was decreased, it remained at that dose or was reduced further on subsequent dosing according to Table 1 . Patients who developed both grade 4 hematologic and grade 4 non-hematologic toxicity were withdrawn from the study.
Inclusion and exclusion criteria
Patients with a histologically confirmed diagnosis of metastatic colorectal cancer were eligible to participate in this study. Other eligibility criteria included requirement of at least one bi-dimensionally measurable lesion, Karnofsky performance status at least 70 (ambulatory and capable of self-care), age at least 18 years, life expectancy at least 12
Evaluation of response
Anti-tumor activity was evaluated according to SWOG response criteria [11] . All patients were required to have measurable disease. The maximum perpendicular diameters of individual measurable lesions were recorded. These diameters were then multiplied and summed if more than one lesion was present. Definitions of measurable, evalu- Non-evaluable disease included: pleural effusions, ascites and disease documented by indirect evidence only (e.g., CEA).
The primary end point of the study was response rate. Complete response (CR) was defined as complete disappearance of all measurable, evaluable and nonevaluable disease, no new lesions, and no disease-related symptoms (including abnormal markers or other laboratory values) confirmed by two consecutive examinations at least four weeks apart. Partial response (PR) was defined as at least a 50% decrease below the baseline in the sum of products of the perpendicular diameters of all measured lesions confirmed by two consecutive examinations at least four weeks apart, with no progression of any other disease (evaluable, nonevaluable or measurable), and no appearance of new lesions. Stable disease (SD) was defined as reduction of less than 50% in tumor measurement as defined above or an increase of less than 25% in the size of all measured lesions, with no progression of any other disease. Progressive disease (PD) was defined as an increase of greater than 25% in the sum of products of all measured lesions over the smallest sum observed, clear worsening of evaluable disease, the appearance of new lesion(s) or reappearance of any old lesion which had disappeared, development of serosal effusion with cytologic confirmation of malignancy, and/or failure to return for evaluation due to death or deteriorating condition, unless clearly unrelated to cancer. able, and non-evaluable disease were adapted from definitions established by SWOG. Measurable disease required lesions with clearly defined margins that were measurable by one of the following methods: direct measurement, medical photograph (skin or oral lesions) or plain X-ray with at least one diameter 0.5 cm or greater (bone lesions not included), CT, MRI, or other imaging scan with both diameters greater than the distance between cuts of the imaging study, or palpation with both diameters 2 cm or greater. If an organ had too many lesions to measure, three lesions were selected for measurement at baseline. The remaining measurable lesions in that organ were recorded as evaluable disease for the purpose of determining objective tumor response. Evaluable disease included: masses with poorly defined margins measurable in only one dimension, lesions with both diameters less than 0.5 cm, lesions on scan with either diameter smaller than the distance between cuts, palpable lesions with either diameter less than 2 cm, and bone disease.
Study assessments
Screening assessments were completed within two weeks prior to the first dose of study drug to determine the eligibility of potential patients. These included: medical history, Karnofsky performance status, physical examination, laboratory testing including hematology, clinical chemistry, urinalysis and estimated creatinine clearance, 12-lead electrocardiogram and assessment of measurable, evaluable, and nonevaluable disease. At a minimum, a chest X-ray and abdominal/pelvic CTor MRI were required. The following assessments were completed within 72 hours prior to the first dose of study drug for each course: physical examination, body weight for calculation of body surface area, Karnofsky performance status, laboratory testing including hematology, clinical chemistry, and urinalysis, assessment of clinical signs and symptoms of cancer and assessment of adverse experiences. Assessment of measurable, evaluable, and non-evaluable disease was Table 2 . Patient characteristics according to treatment history -n (%) (total number of patients, n = 74). 
Results

Patient demographics
Between August 1995 and October 1996, 75 patients were enrolled on the study. One patient who was enrolled never received treatment. The characteristics of the patients treated are listed in Table 2 . Only patients who received study drug have been included in this report. Seventy-two had measurable disease, and two patients without measurable disease were enrolled and treated in violation of protocol. Seven patients were treated in violation of protocol eligibility requirements; five with estimated creatinine clearance < 50 ml/min, one with malabsorption syndrome and one who had progressed following therapy with 5-FU-levamisole. One patient received a course of therapy with eniluracil-5-FU but elected not to return for a follow-up evaluation.
Response to treatment
All responses were partial responses and were observed in patients in the previously untreated stratum. Five responses were observed in the 24 patients in the previously untreated stratum for an overall response rate of 21% (95% confidence interval (95% CI): 7. (13) 2 (3) 21 (28) 35 (47) 11 (15) 7 (9) 59 (80) (7) 5(7) of maximum hematologic Grade 1
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Grade 4 20 (27) 1 (1) 3 (1) 8 (11) sponse rate in this stratum was 17% (2 of 12) for patients treated with eniluracil-5-FU and 25% (3 of 12) for patients treated with eniluracil-5-FU-LV, respectively. Durations of response were 16.1 and 33.9 weeks in the patients treated with eniluracil-5-FU and 16.3, 49.6 and 51.1 weeks in the patients treated with eniluracil-5-FU-LV. No responses were observed in refractory patients. Stable disease at the time of first scheduled reassessment was observed in 38% (9 of 24) of previously untreated patients and 30% (15 of 50) of refractory patients. Stable disease was observed at the time of first scheduled reassessment in 20% (5 of 25) of patients in the primary resistance sub-stratum and in 40% (10 of 25) of patients in the acquired resistance sub-stratum. The median progression-free survival for previously untreated and refractory patients was 18.9 weeks and 8.7 weeks, respectively. Progression of disease was observed in 42% (10 of 24) of patients at the time of first tumor reassessment in the previously untreated stratum and 56% (28 of 50) in the refractory disease stratum. Response data were not available for 5 of the 74 treated patients for the following reasons: 2 patients did not have tumor measurements reported, 2 patients had evaluable disease only at the time of enrollment and 1 patient withdrew consent after the first course of treatment.
Toxicity
The most frequently reported adverse events, reasonably attributable to study therapy in order of decreasing frequency, are shown in Table 3 . The most frequently reported adverse event was diarrhea, which occurred at any grade in 51% of patients. Diarrhea was also the most frequently reported grade 3-4 nonhematologic toxicity and was reported at these intensities in 7% of patients. The incidence of treatment-related diarrhea of any grade was 67% in the eniluracil-5-FU-LV treated patients and 41% in the eniluracil-5-FU treated patients, while grade 3-4 diarrhea occurred in 3% and 9% of patients in each treatment group, respectively. No cases of grade 2 or greater hand-foot syndrome were reported. A summary of the hematologic toxicity observed is presented in Table 4 . Grade 3 and 4 granulocytopenia were each observed in 27% of patients, overall. Forty-seven percent of patients treated with eniluracil-5-FU-LV developed grade 3-4 granulocytopenia as did sixty percent of patients treated with eniluracil-5-FU which lasted a median of 7 days (range 1-15 days).
During the first three months of the study, 20 patients were enrolled on the eniluracil-5-FU treatment arm. Six of these patients were hospitalized with grade 4 neutropenia and sepsis. As a consequence, the method of dose calculation for 5-FU was changed to rounding down (instead of up) to the nearest 5 mg. After this adjustment, only four additional patients out of the remaining 54 were hospitalized for neutropenic sepsis. Three of these patients were on the eniluracil-5-FU-LV arm. There were no treatment-related deaths on either arm of the study.
Duration of treatment
In the previously untreated stratum, patients treated with eniluracil-5-FU remained on therapy for a range of 1-14 courses (median 4) and those treated with eniluracil-5-FU-LV remained on therapy for a range of 1-38 courses (median 6.5). One patient had progressive disease after 20 courses but received 38 courses of therapy in violation of protocol. In the refractory disease stratum, patients treated with eniluracil-5-FU remained on therapy for a range of 1-18 courses (median 2), and those treated with eniluracil-5-FU-LV remained on therapy for a range of 1-15 courses (median 2). Fiftynine patients (80%) discontinued therapy due to progressive disease, eight (11%) discontinued due to adverse events, three (4%) withdrew consent, two (3%) discontinued due to death, one (1%) because maximum benefit was obtained and one (1%) because the study was discontinued by the sponsor.
Discussion
Colorectal cancer is a major public health concern in North America and Western Europe. In the US over 100,000 patients received 5-FU based chemotherapy for the treatment of CRC in 1998 [12] . Treatment requires a major time and resource commitment for both patients and the health care system. Until recently, 5-FU was the only chemotherapeutic agent with reproducible efficacy against colon cancer in either the adjuvant or metastatic setting, and it remains the agent most frequently administered to patients with this disease. Several agents have recently been developed as oral alternatives to 5-FU in an attempt to improve patient convenience and decrease clinic resource utilization while maintaining or improving the efficacy of i.v. 5-FU. Orally administered chemotherapy would convert much of the treatment of CRC from office to home-based therapy.
Eniluracil is an inactivator of DPD, the principal and rate-limiting enzyme of 5-FU catabolism. Through DPD inactivation eniluracil permits 5-FU to be administered orally with highly reproducible bioavailability [13] . Inactivation of DPD in the liver, gastrointestinal mucosa and other tissues allows therapeutic plasma levels of drug to be achieved following oral administration of extremely low doses of 5-FU. Two effective and welltolerated eniluracil-5-FU administration schedules were evaluated in phase I studies and advanced to the phase II setting for treatment of patients with metastatic CRC [10, 14] . These schedules were designed to mimic schedules of 5-FU or 5-FU/LV commonly used in clinical practice. The schedule used in this study is similar to the NCCTGMayo Clinic 5-FU plus low-dose LV regimen. The other is a 28-day administration schedule that simulates the pharmacokinetics of prolonged continuous infusion 5-FU.
This study was designed as a pilot study to investigate the activity of eniluracil-5-FU given by the 5-day schedule with or without LV to patients with metastatic CRC who had not been previously treated or who had progressive disease despite therapy with 5-FU-LV. The results of this study establish that eniluracil-5-FU given alone or with oral LV possesses activity in previously untreated patients and merits further investigation in larger clinical trials. This activity appears to be comparable to that reported for traditional schedules of i.v. 5-FU-LV. The presence of anti-tumor activity in the previously-treated population is less clear. No responses were observed in that group, however, a number of patients did demonstrate prolonged stabilization of disease while on therapy. Thus, although tumor DPD may remain a mechanism of resistance, thymidylate synthase upregulation may also play an important role, especially in previously treated patients.
The primary toxicity observed in this study was myelosuppression. During the first three months of the study, 6 of 20 patients treated were hospitalized with grade 4 neutropenia and sepsis. This higher than expected frequency of myelosuppression may have been due to a higher dose of eniluracil used in this study compared to that given to patients in the phase I study. The dose of eniluracil had been increased to ensure maximal inactivation of DPD, and more complete inactivation of DPD may have increased 5-FU exposure and toxicity. Changes in the method of dose calculation for 5-FU from rounding up to rounding down to the nearest 5 mg. resulted in mitigation of toxicity in the remaining 54 patients such that only 4 (7%) were hospitalized for neutropenic sepsis. In addition, the effects of the myelo-suppression were manageable, as no septic deaths were observed in any patients treated on this study. The only other toxicity that occurred in appreciable frequency was diarrhea, which was severe (grade 3 or 4) in only 7% of patients.
In view of the activity, favorable toxicity pattern and convenience of eniluracil-5-FU, further evaluation of this therapy has subsequently been conducted. Additional phase II studies of eniluracil-5-FU and eniluracil-5-FU-LV given on the same schedule to patients with metastatic CRC have been undertaken by the NCCTG and CALGB. A preliminary response rate of 18% was reported for both of these studies, but final results are pending at this time [15, 16] . Toxicity observed in the two cooperative group studies was similar to that reported here, however the frequencies of grade 3-4 diarrhea (21%) and grade 4 granulocytopenia (46%) were higher in the CALGB study. This may be due to differences in dose rounding methods used in the two studies.
Preliminary results of a multicenter phase II study in patients with previously untreated metastatic CRC have also been reported for the 28-day schedule of eniluracil-5-FU, with a response rate of 27% [17] . Diarrhea was the major and dose-limiting toxicity observed with that schedule, but it still occurred at a low and acceptable frequency. In contrast to the results presented here, myelosuppression was relatively minor with the 28-day schedule. Because the toxicity profile of the 28-day schedule was better than that seen with the 5-day schedule, the former was chosen for phase III development. The phase III trials did not include LV because of the lack of evidence for a beneficial effect of the addition of LV to continuous infusion 5-FU. Two randomized multicenter phase III trials of eniluracil-5-FU given on the 28-day schedule versus 5-FU-LV given by the Mayo clinic schedule in patients with previously untreated metastatic colorectal cancer have recently completed accrual. In addition, a randomized phase III study of eniluracil-5-FU versus prolonged continuous infusion 5-FU is currently being conducted by the Eastern Cooperative Oncology Group (E5296) in patients with previously untreated metastatic CRC.
